Developing an approach to assessing the political feasibility of global collective action and an international agreement on antimicrobial resistance

被引:10
作者
Rogers Van Katwyk S. [1 ,2 ]
Danik M.É. [1 ]
Pantis I. [1 ]
Smith R. [1 ]
Røttingen J.-A. [1 ,3 ,4 ,6 ]
Hoffman S.J. [1 ,5 ,6 ]
机构
[1] Global Strategy Lab, Centre for Health Law, Policy & Ethics, Faculty of Law, University of Ottawa, Ottawa
[2] School of Epidemiology, Public Health, and Preventive Medicine, University of Ottawa, Ottawa
[3] Division of Infection Control & Environmental Health, Norwegian Institute of Public Health, Oslo
[4] Department of Health and Society, University of Oslo, Oslo
[5] Department of Clinical Epidemiology & Biostatistics and McMaster Health Forum, McMaster University, Hamilton, ON
[6] Department of Global Health & Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA
基金
加拿大健康研究院;
关键词
AMR; Antibiotic Resistance; Global Health; International Affairs; Political Feasibility;
D O I
10.1186/s41256-016-0020-9
中图分类号
学科分类号
摘要
Background: Antimicrobial resistance (AMR) is a global issue. International trade, travel, agricultural practices, and environmental contamination all make it possible for resistant microbes to cross national borders. Global collective action is needed in the form of an international agreement or other mechanism that brings states together at the negotiation table and commits them to adopt or implement policies to limit the spread of resistant microorganisms. This article describes an approach to assessing whether political and stakeholder interests can align to commit to tackling AMR. Methods: Two dimensions affecting political feasibility were selected and compared across 82 countries: 1) states’ global influence and 2) self-interest in addressing AMR. World Bank GDP ranking was used as a proxy for global influence, while human antibiotic consumption (10-year percent change) was used as a proxy for self-interest in addressing AMR. We used these data to outline a typology of four country archetypes, and discuss how these archetypes can be used to understand whether a proposed agreement may have sufficient support to be politically feasible. Results: Four types of countries exist within our proposed typology: 1) wealthy countries who have the expertise and financial resources to push for global collective action on AMR, 2) wealthy countries who need to act on AMR, 3) countries who require external assistance to act on AMR, and 4) neutral countries who may support action where applicable. Any international agreement will require substantial support from countries of the first type to lead global action, and from countries of the second type who have large increasing antimicrobial consumption levels. A large number of barriers exist that could derail efforts towards global collective action on AMR; issues of capacity, infrastructure, regulation, and stakeholder interests will need to be addressed in coordination with other actors to achieve an agreement on AMR. Conclusions: Achieving a global agreement on access, conservation, and innovation – the three pillars of AMR – will not be easy. However, smaller core groups of interested Initiator and Pivotal Countries could develop policy and resolve many issues. If highly influential countries take the lead, agreements could then be scaled up to achieve global action. © 2016, The Author(s).
引用
收藏
相关论文
共 37 条
  • [1] Rethinking the Way We Fight Bacteria, (2015)
  • [2] The Chief Public Health Officer’s Report on the State of Public Health in Canada, 2013: Infectious Disease - the Never-Ending Threat., (2013)
  • [3] Barlam T.F., Gupta K., Antibiotic resistance spreads internationally across borders, J Law Med Ethics, 43, pp. 12-16, (2015)
  • [4] Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations United Kingdom 2014
  • [5] Antimicrobial Resistance - Global Report on Surveillance, Organization WH, Editor. Geneva: WHO Press, (2014)
  • [6] Hoffman S.J., Outterson K., What will It take to address the global threat of antibiotic resistance?, J Law Med Ethics, 43, 2, pp. 363-368, (2015)
  • [7] Hollis A., Maybarduk P., Antibiotic resistance is a tragedy of the commons that necessitates global cooperation, J Law Med Ethics, 43, pp. 33-37, (2015)
  • [8] Daulaire N., Bang A., Tomson G., Kalyango J.N., Cars O., Universal access to effective antibiotics is essential for tackling antibiotic resistance, J Law Med Ethics, 43, pp. 17-21, (2015)
  • [9] Resolution WHA 67.25: Antimicrobial resistance, (2014)
  • [10] WHO Global Strategy for Containment of Antimicrobial Resistance, (2001)